Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Trial Evaluating Nutritional Fiber in Digestive Symptoms of Endometriosis (TEND)

9. November 2026 aktualisiert von: LOAM Science

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Mechanistic Effects of a Multi-Fiber Prebiotic Dietary Supplement (LOAM) on the Gut and Vaginal Microbiome, Gastrointestinal Well-Being, and Quality-of-Life Parameters in Women With Endometriosis and Co-Existing Gastrointestinal Symptoms

This study is a double-blind, randomized, placebo-controlled study that evaluates the safety and tolerability of a fiber-based dietary supplement and the mechanistic and structure-function effects of that supplement on the gut and vaginal microbiome, gastrointestinal well-being, and quality-of-life parameters in 140 women with endometriosis and co-existing gastrointestinal symptoms over 12 weeks. The primary objective is to evaluate the safety and tolerability of the supplement, measured by the incidence and severity of gastrointestinal adverse events (AEs) and discontinuations. Secondary objectives include assessing the fibers impact on gastrointestinal symptoms and quality of life through the use of custom questionnaires built for the study population and evaluation of other endometriosis related parameters such as pelvic discomfort. Exploratory objectives focus on the exploration of the gut and vaginal microbiomes, their connection to endometriosis, and how they are impacted by the study product.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

140

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • Vereinigte Staaten
    • California
      • San Francisco, California, Vereinigte Staaten, 94109
        • Rekrutierung
        • Alethios
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 45 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Confirmed diagnosis of endometriosis (by imaging, laparoscopy, or physician clinical assessment).
  • Enriched gastrointestinal phenotype: self-reported gastrointestinal symptoms on at least 3 days per week for the preceding 3 months, including at least one of bloating, constipation, or abdominal discomfort
  • Predominantly Bristol Stool Scale Type 1-3 (constipation-predominant), or self-reported bloating as a dominant symptom.
  • Stable hormonal status: either no hormonal therapy, or stable hormonal therapy (combined oral contraceptive, progestin, or GnRH analogue) for at least 3 months with no planned change during the study.
  • Estimated habitual dietary fiber intake below 25 g/day based
  • Willingness to share menstrual cycle data.
  • Willing to maintain stable diet, physical activity, and medication regimens throughout the study.
  • Able to provide electronic informed consent and to comply with stool and vaginal self-sampling procedures.
  • Ownership and consistent use of a home body-weight scale for the duration of the study, to support the standardized at-home morning weighing protocol.

Exclusion Criteria:

  • Inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, or other organic gastrointestinal disease.
  • Severe irritable bowel syndrome (IBS) requiring active pharmacological management. Mild-to-moderate overlap is permitted as part of the enrichment strategy.
  • Antibiotic use within 8 weeks prior to baseline or anticipated during the study.
  • Probiotic, prebiotic, or fiber supplement use within 4 weeks prior to baseline (washout required).
  • Major gastrointestinal surgery, excluding appendectomy or cholecystectomy more than 6 months prior, and excluding surgical intervention for endometriosis.
  • Current pregnancy, breastfeeding, or plans to conceive during the study.
  • Severe constipation requiring regular prescription laxatives.
  • Significant renal, hepatic, cardiac, or endocrine disease.
  • Active malignancy.
  • Known allergy or intolerance to any LOAM fiber component.
  • Significant dietary change or weight-loss intervention within the preceding 3 months.
  • Use of medications known to significantly alter gut motility or the microbiome (for example, recent metformin initiation, regular opioid use, or chronic proton-pump inhibitor use), per investigator judgment.
  • Any surgical intervention for endometriosis (including laparoscopy, laparotomy, or endometrioma excision) within the 6 months prior to screening, as post-surgical physiological changes may confound symptom and biomarker assessments.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Fiber Supplement

Fiber supplement providing 20 grams/day of dietary fiber. Taken as a scoop of powder added to a drink twice daily.
Nahrungsergänzungsmittel: Fiber

Dietary fiber blend containing six prebiotic fibers.
Placebo-Komparator: Placebo Control

Placebo control. Taken as a scoop of powder added to a drink twice daily.
Nahrungsergänzungsmittel: Placebo

Placebo control

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence and severity of GI adverse events (AEs) and discontinuations.
Zeitfenster: An adverse event questionnaire will be administered at baseline and at Week 4, Week 6, Week 8, and Week 12 of supplementation. Adverse events will also be collected ad hoc throughout the study period via a reporting form.

To evaluate the safety and tolerability of the fiber blend.
An adverse event questionnaire will be administered at baseline and at Week 4, Week 6, Week 8, and Week 12 of supplementation. Adverse events will also be collected ad hoc throughout the study period via a reporting form.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in a custom gut health questionnaire
Zeitfenster: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

A custom gut health questionnaire using a 5-point Likert Scale (1-5) where 1 is no symptoms and 5 is the worst symptoms designed to evaluate GI symptoms relevant to endometriosis.
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
DASS-21
Zeitfenster: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Self-reported mental health tool to evaluate depression, anxiety, and stress that uses a 4-point Likert Scale (0-3) where 0 is not applicable and 3 is highly applicable.
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Pelvic discomfort duration over 24 hours
Zeitfenster: From baseline sample collection through the end of supplementation (Daily).

Evaluation of pelvic discomfort associated with endometriosis over the previous 24 hours using a 0-24 scale, where 0 is no hours of pelvic discomfort and 24 is pelvic discomfort for the entire duration of the last 24 hours.
From baseline sample collection through the end of supplementation (Daily).
Pelvic discomfort severity
Zeitfenster: From baseline sample collection through the end of supplementation (daily).

Pelvic discomfort severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort.
From baseline sample collection through the end of supplementation (daily).
Body Weight
Zeitfenster: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Performed at home using a scale
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Gut Microbiome Composition
Zeitfenster: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.

Evaluation of the gut microbiome composition using shotgun metagenomic sequencing.
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
Gut Microbiome Function
Zeitfenster: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.

Evaluation of the gut microbiome function using shotgun metagenomic sequencing.
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
Vaginal Microbiome Composition
Zeitfenster: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.

Evaluation of the vaginal microbiome composition using shotgun metagenomic sequencing.
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
Custom endometriosis quality of life survey
Zeitfenster: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

A custom survey designed to assess the impact of endometriosis on an individuals quality of life. Questions are scored using a 5-point Likert Scale (1-5) where 1 is no impact on quality of life and 5 is the highest level of impact.
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Vaginal Microbiome Function
Zeitfenster: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.

Evaluation of the vaginal microbiome function using shotgun metagenomic sequencing.
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
Endometriosis-related Medication Use
Zeitfenster: From enrollment through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Medication use assess by open-ended questionnaire.
From enrollment through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Deep dyspareunia
Zeitfenster: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Deep dyspareunia severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort.
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Dysmenorrhea
Zeitfenster: From baseline through the conclusion of supplementation (daily).

Dysmenorrhea severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort.
From baseline through the conclusion of supplementation (daily).
Non-menstrual pelvic discomfort
Zeitfenster: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Non-menstrual pelvic discomfort severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort.
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Dyschezia
Zeitfenster: From baseline through the conclusion of supplementation (daily).

Dyschezia severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort.
From baseline through the conclusion of supplementation (daily).
Productivity Impairment
Zeitfenster: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Measured using the Work Productivity and Activity Impairment Questionnaire, which includes open ended questions to assess hours missed as well as personal assessments of productivity using a 10 point numerical rating scale (0-10) with zero being no effect and ten being highly impacted.
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
Bloating severity and abdominal girth
Zeitfenster: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Bloating severity assessed using a 10 point numerical rating scale (0-10) with zero being no bloating and ten being the highest level of bloating and abdominal girth measured by tape measure.
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

LOAM Science

Mitarbeiter

Alethios, Inc.

Ermittler

  • Hauptermittler: Bryce Jarman, PhD, LOAM Science

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. Oktober 2026

Primärer Abschluss (Geschätzt)

1. Juni 2027

Studienabschluss (Geschätzt)

1. September 2027

Studienanmeldedaten

Zuerst eingereicht

6. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Oktober 2026

Zuerst gepostet (Tatsächlich)

15. Oktober 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • LOA001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

The data is proprietary data.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren